Companies

VKTX · Biotech

Viking Therapeutics, Inc.

SEC company filings

Reported cash

USD 677,609,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · Clinical readout window

VK2735 · maintenance Part 2 results · 2027

Announced Oct 28, 2026 · Announced window

Official announcement
Source wording

participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. Study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33. The company expects the results from Part 2 of this study to be available in 2027.

Clinical readout window

VANQUISH · extension study results · 2028

Announced Oct 28, 2026 · Announced window

Official announcement
Source wording

VANQUISH Extension Studies to Commence in 1Q27. Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks. The extension studies will provide important long-term safety and efficacy data and afford subjects the opportunity to continue receiving VK2735 upon completion of the primary dosing periods. In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.

Drug pipeline

8 programs · 13 verified studies

Placebos

Phase

Phase2

Study status

Completed
View details

Viking Therapeutics, Inc.

IndicationNASH - Nonalcoholic Steatohepatitis

Actual study completion2024-01-26

SC VK3019

Phase

Phase1

Study status

Recruiting
View details

Viking Therapeutics, Inc.

IndicationObese Adults

Estimated study completion2026-11

VK0214

Phase

Phase1

Study status

Completed
View details

Viking Therapeutics, Inc.

IndicationAdrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

Actual study completion2024-11-08

VK2735

Phase

Phase1

Study status

Completed
View details

Viking Therapeutics, Inc.

IndicationWeight Loss; NASH

Actual study completion2024-12-03

VK2735

Phase

Phase2

Study status

Completed
View details

Viking Therapeutics, Inc.

IndicationWeight Loss

Actual study completion2024-04-02

VK2735

Phase

Phase2

Study status

Completed
View details

Viking Therapeutics, Inc.

IndicationWeight Loss

Actual study completion2025-08-15

VK2735

Phase

Phase3

Study status

Active not recruiting
View details

Viking Therapeutics, Inc.

IndicationWeight Loss

Estimated study completion2027-08-01

VK2735

Phase

Phase3

Study status

Active not recruiting
View details

Viking Therapeutics, Inc.

IndicationWeight Loss

Estimated study completion2027-08-01

VK2735

Phase

Phase3

Study status

Not yet recruiting
View details

Viking Therapeutics, Inc.

IndicationWeight Loss

Estimated study completion2028-08

VK2735 Drug

Phase

Phase1

Study status

Completed
View details

Viking Therapeutics, Inc.

IndicationWeight Loss; NASH

Actual study completion2024-12-03

1 / 2

0 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.